With the average cost to bring a new drug to market surging upwards of $2.5 billion, our client
wanted to get in front of any mentions of trial drugs before they were officially available. GroupSense worked closely with the client, a global pharmaceutical company, to fight back against IP fraud.
Our threat intelligence analysts identified a syndicate claiming to have access to name-brand medications. Whether the activities were from the physical theft of medication, or manufacturing of counterfeit drugs, the end result was the same: a negative impact on the client's reputation. A response was needed.
Armed with superior intelligence provided by GroupSense, our client quickly took action to prevent further activities from the threat actor group responsible. Understanding how an individual threat actor or group operates empowered our client to modify their own processes in the future to prevent recurrences.